ORPHA.CO - Orphazyme A/S

Copenhagen - Copenhagen Real Time Price. Currency in DKK
61.00
-0.80 (-1.29%)
At close: 4:59PM CEST
Stock chart is not supported by your current browser
Previous Close61.80
Open62.40
Bid60.60 x 0
Ask61.20 x 0
Day's Range60.60 - 62.40
52 Week Range41.10 - 76.00
Volume14,005
Avg. Volume17,047
Market Cap1.219B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-14.30
Earnings DateAug 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est121.75
  • GlobeNewswire

    Orphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event

    Copenhagen, Denmark, September 17, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, has been invited to participate in a meeting hosted by the National Organization for Rare Disorders (NORD) and the Critical Path Institute (C-PATH) to launch their joint initiative: the Rare Disease Cures Accelerator Data and Analytics Platform (RDCA-DAP). Today, Orphazyme’s Chief Medical Officer, Thomas Blaettler, MD, will participate in a moderated panel discussion on “Current Challenges in Rare Disease Drug Development,” during which he will share Orphazyme’s experiences in working to bring new treatments for orphan diseases to market.

  • Thomson Reuters StreetEvents

    Edited Transcript of ORPHA.CO earnings conference call or presentation 28-Aug-19 9:00am GMT

    Q2 2019 Orphazyme A/S Earnings Call

  • GlobeNewswire

    Orphazyme announces Interim Report First Half 2019

    Copenhagen, Denmark, August 28, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights. Arimoclomol is also in clinical development in three other indications of very high unmet need: Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM), and Gaucher disease.

  • GlobeNewswire

    Orphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital

    Copenhagen, Denmark, August 27, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has entered into a structured debt facility (Loan Agreement) with Kreos Capital VI (UK) Limited (Kreos) to secure funding of EUR 9 million.

  • GlobeNewswire

    Orphazyme Interim Report First Half 2019 Presentation

    Investor news                                                                                                            Orphazyme A/SCompany Registration No. 32266355.

  • GlobeNewswire

    Major shareholder announcement

    Company announcement                                                                                                                                               No. 24/2019.

  • CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
    PR Newswire

    CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C

    LOS ANGELES, July 30, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that following a positive meeting with the U.S. Food and Drug Administration (FDA), arimoclomol licensee Orphazyme A/S (ORPH.CO) remains on track to submit a New Drug Application (NDA) for arimoclomol in Niemann-Pick Disease Type C (NPC) in the first half of 2020. Orphazyme also announced plans to introduce an Early Access Program for NPC in the fall of 2019.

  • GlobeNewswire

    Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

    Orphazyme A/SCompany announcement                                                                                                                   No..

  • GlobeNewswire

    New phantom share-based incentive program

    Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company introduces a four-year phantom share-based incentive program in July 2019 for, in general, all employees other than the Executive Management team (the “Program”). The Program is based on phantom shares and entitles the participants to a potential cash bonus if there has been an increase in Orphazyme’s share price of at least 20% compared to the entry price at the introduction of the Program, as further described below.

  • GlobeNewswire

    New share-based incentive program

    Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company introduces a new share-based incentive program (the “LTIP”). The LTIP has been implemented in accordance with Orphazyme’s Remuneration Policy, including the guidelines for incentive pay adopted at Orphazyme’s annual general meeting on March 27, 2019. Under the LTIP, the Executive Management as well as certain key employees of Orphazyme have subscribed for or acquired a number of shares (“Investment Shares”).

  • GlobeNewswire

    New incentive program for the Board of Directors of Orphazyme

    The purpose of the Board Incentive Program is to attract and retain qualified members of the Board of Directors as share-based incentives are commonly used among competing international biotech and pharmaceutical companies.

  • GlobeNewswire

    Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)

    Anders Hinsby, Chief Executive Officer of Orphazyme, said: “We are very pleased with the collaborative interactions we have had with the FDA who provided us with thorough guidance on data presentation in the NDA for arimoclomol in the US for NPC.

  • GlobeNewswire

    Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis

    Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has completed enrollment in its phase 3 trial evaluating arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS) ahead of schedule. Headline results from the full analysis remain on track for the first half of 2021. The trial completed enrollment sooner than anticipated thanks to support from the global ALS community and the participation of hundreds of people living with ALS and their care partners.

  • GlobeNewswire

    Orphazyme appoints Kim Stratton as Chief Executive Officer

    Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company’s Board of Directors has appointed Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby. Kim Stratton will take up her new position on October 1, 2019. As Orphazyme enters a new chapter in its development, from being an entrepreneurial R&D company to a company with significant growth aspirations, an emerging late-stage pipeline and moving into the pre-commercial phase, Anders Hinsby initiated discussions with the Board of Directors to resign from his position as Chief Executive Officer.

  • CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
    PR Newswire

    CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

    Patent Covers the Formulation, Storage, Delivery and Administration of Aldoxorubicin at Room Temperature and Eliminates the Need for Cold Handling LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation ...

  • CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
    PR Newswire

    CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C

    LOS ANGELES, June 19, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for arimoclomol in Niemann-Pick disease Type C (NPC).  Based on advice received from the EMA's Scientific Advice Working Group, Orphazyme expects to submit the arimoclomol MAA in the first half of 2020.

  • GlobeNewswire

    Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

    Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has received constructive advice from the European Medicines Agency (EMA)’s Scientific Advice Working Group in response to the request for advice submitted to the agency. Anders Hinsby, Chief Executive Officer, said: “We are pleased with the advice received from EMA, which provides good guidance on topics that we will take into careful consideration as we continue the preparation of a Marketing Authorization Application for arimoclomol in Europe.

  • How Do Analysts See Orphazyme A/S (CPH:ORPHA) Performing In The Next Couple Of Years?
    Simply Wall St.

    How Do Analysts See Orphazyme A/S (CPH:ORPHA) Performing In The Next Couple Of Years?

    In December 2018, Orphazyme A/S (CPH:ORPHA) released its latest earnings announcement, which signalled company...

  • CytRx Corporation Reports First Quarter 2019 Financial Results
    PR Newswire

    CytRx Corporation Reports First Quarter 2019 Financial Results

    Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing ...

  • CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
    PR Newswire

    CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

    "We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.

  • CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
    PR Newswire

    CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

    CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical ...

  • CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
    PR Newswire

    CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S

    CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , April 29, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a ...

  • GlobeNewswire

    Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled

    Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that its Phase II/III trial of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM) is fully enrolled. Anders Hinsby, Chief Executive Officer, said: “We are truly delighted about the strong support for this trial from the patient community and clinicians, which has been paramount to achieving enrollment at an impressive rate. Sporadic Inclusion Body Myositis is a relentlessly progressive and debilitating disease with no current treatment options available and we cannot waste any time in completing this trial in order to evaluate the potential of arimoclomol as a treatment for this disease”.